keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/28736505/estimating-the-cost-effectiveness-of-daclatasvir%C3%A2-%C3%A2-sofosbuvir-versus-sofosbuvir%C3%A2-%C3%A2-ribavirin-for-patients-with-genotype-3-hepatitis-c-virus
#1
Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan
BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28727784/an-ns5a-single-optimized-method-to-determine-genotype-subtype-and-resistance-profiles-of-hepatitis-c-strains
#2
Elisabeth Andre-Garnier, Bernard Besse, Audrey Rodallec, Olivier Ribeyrol, Virginie Ferre, Caroline Luco, Laura Le Guen, Nathalie Bourgeois, Jérôme Gournay, Eric Billaud, François Raffi, Marianne Coste-Burel, Berthe-Marie Imbert-Marcille
The objective was to develop a method of HCV genome sequencing that allowed simultaneous genotyping and NS5A inhibitor resistance profiling. In order to validate the use of a unique RT-PCR for genotypes 1-5, 142 plasma samples from patients infected with HCV were analysed. The NS4B-NS5A partial region was successfully amplified and sequenced in all samples. In parallel, partial NS3 sequences were analyzed obtained for genotyping. Phylogenetic analysis showed concordance of genotypes and subtypes with a bootstrap >95% for each type cluster...
2017: PloS One
https://www.readbyqxmd.com/read/28719013/in-an-era-of-highly-effective-treatment-hepatitis-c-screening-of-the-general-population-of-the-united-states-for-hepatitis-c-should-be-considered
#3
Zobair Younossi, Deidre Blissett, Rob Blissett, Linda Henry, Youssef Younossi, Rachel Beckerman, Sharon Hunt
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment with all oral direct acting antiviral agents (DAA's) achieve sustained virologic response (SVR) rates of 98%. Re-assessment of general US population screening for HCV is imperative. This study compared the cost-effectiveness (CE) of three HCV screening strategies: screen all (SA), screen Birth Cohort (BCS), and screen high risks (HRS). METHODS: Using a previous designed decision-analytic Markov model, estimations of the natural history of HCV and CE evaluation of the three HCV screening strategies over a lifetime horizon in the US population was undertaken...
July 18, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28715911/hepatitis-c-treatment-regimens-are-cost-effective-but-compared-with-what
#4
T Joseph Mattingly, Julia F Slejko, C Daniel Mullins
BACKGROUND: Numerous economic models have been published evaluating treatment of chronic hepatitis C virus (HCV) infection, but none provide a comprehensive comparison among new antiviral agents. OBJECTIVE: Evaluate the cost-effectiveness of all recommended therapies for treatment of genotypes 1 and 4 chronic HCV. METHODS: Using data from clinical trials, observational analyses, and drug pricing databases, Markov decision models were developed for HCV genotypes 1 and 4 to compare all recommended drugs from the perspective of the third-party payer over a 5-, 10-, and 50-year time horizon...
July 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28715086/optimal-use-of-transient-elastography-and-acoustic-radiation-force-impulse-to-stage-liver-fibrosis-in-hiv-hcv-coinfected-patients-in-clinical-practice
#5
Juan José López, Núria Pérez-Àlvarez, Raul V Rodríguez, Antoni Jou, Pere Carbonell, José A Jiménez, Laura Soldevila, Montserrat Tenesa, Jordi Tor, Bonaventura Clotet, Jordi Bechini, Cristina Tural
OBJECTIVES: Liver fibrosis (LF) is crucial for the individualized management of patients with hepatitis C virus (HCV). We evaluated the concordance between two noninvasive methods for staging LF, transient elastography (TE) and acoustic radiation force impulse (ARFI), in patients coinfected with human immunodeficiency virus and HCV. We propose an algorithm for optimal use of both techniques in routine clinical practice. METHODS: A total of 89 human immunodeficiency virus/HCV-coinfected patients underwent TE and ARFI on the same day...
July 17, 2017: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/28699869/hepatitis-c-virus-in-vitro-replication-is-efficiently-inhibited-by-acridone-fac4
#6
Guilherme Rodrigues Fernandes Campos, Cíntia Bittar, Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Mariana Nogueira Batista, Eder Ramos Paganini, Letícia Ribeiro de Assis, Christopher Bartlett, Mark Harris, Vanderlan da Silva Bolzani, Luis Octavio Regasini, Paula Rahal
Hepatitis C virus (HCV) affects about 170 million people worldwide. The current treatment has a high cost and variable response rates according to the virus genotype. Acridones, a group of compounds extracted from natural sources, showed potential antiviral actions against HCV. Thus, this study aimed to evaluate the effect of a panel of 14 synthetic acridones on the HCV life cycle. The compounds were screened using an Huh7.5 cell line stably harbouring the HCV genotype 2a subgenomic replicon SGR-Feo-JFH-1...
July 12, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28698985/a-cinnamon-derived-procyanidin-type-a-compound-inhibits-hepatitis-c-virus-cell-entry
#7
Catherine Fauvelle, Melanie Lambotin, Laura Heydmann, Ekambaranellore Prakash, Sunil Bhaskaran, Mohan Vishwaraman, Thomas F Baumert, Christiane Moog
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon. METHODS AND RESULTS: Using cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry...
July 11, 2017: Hepatology International
https://www.readbyqxmd.com/read/28692208/hcv-antigen-instead-of-rna-testing-to-diagnose-acute-hcv-in-patients-treated-in-the-dutch-acute-hcv-in-hiv-study
#8
Sebastiaan J Hullegie, Corine H GeurtsvanKessel, Annemiek A van der Eijk, Chris Ramakers, Bart J A Rijnders
INTRODUCTION: Affordable and sensitive screening methods for acute hepatitis C (HCV) are necessary to successfully intervene in the current HCV epidemic among HIV-positive men having sex with men. HCV core antigen (Ag) testing has been proven effective in diagnosing chronic HCV-infected patients at low costs. We studied the characteristics of HCV Ag testing in acute HCV-infected HIV-positive patients. Methods Plasma samples were selected from acutely HCV genotype 1-infected patients treated with peginterferon, ribavirin and boceprevir in the Dutch Acute HCV in HIV Study...
June 30, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28691377/effectiveness-of-8-or-12-weeks-of-ledipasvir-and-sofosbuvir-in-real-world-treatment-na%C3%A3-ve-genotype-1-hepatitis-c-infected-patients
#9
M P Curry, E B Tapper, B Bacon, D Dieterich, S L Flamm, L Guest, K V Kowdley, Y Lee, S Milligan, N Tsai, Z Younossi, N H Afdhal
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR). Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naïve to treatment with a baseline HCV RNA <6 million IU/mL can be treated for 8 weeks. This guidance stemmed from a post hoc analysis of the ION 3 clinical trial, which demonstrated similar SVR for patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or 12 weeks...
July 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28689595/economic-burden-of-hepatitis-c-infection
#10
REVIEW
Maria Stepanova, Zobair M Younossi
The economic burden of chronic hepatitis C might exceed $10 billion annually in the United States alone. This disease has a worldwide prevalence of up to 3%, making the global burden of the disease comparably tremendous. The cost of the disease includes direct medical expenses for its hepatic and extrahepatic manifestations, and also indirect costs incurred from impaired quality of life and the loss of work productivity. Recent emergence of treatment options that are not only highly effective and safe but also costly has emphasized the need to study the disease from the economic point of view...
August 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28689590/chronic-hepatitis-c-virus-infection-and-depression
#11
REVIEW
Luigi Elio Adinolfi, Riccardo Nevola, Luca Rinaldi, Ciro Romano, Mauro Giordano
Hepatitis C virus (HCV) infection is a systemic disease with hepatic and extrahepatic manifestations, including neuropsychiatric conditions. Depression is a frequent disorder, which has been reported in one-third of patients with HCV infection and has an estimated prevalence of 1.5 to 4.0 times higher than that observed in patients with chronic hepatitis B virus infection or the general population. HCV seems to play a direct and indirect role in the development of depression. Impaired quality of life and increasing health care costs have been reported for patients with HCV infection with depression...
August 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28685917/on-the-potential-of-a-short-term-intensive-intervention-to-interrupt-hcv-transmission-in-hiv-positive-men-who-have-sex-with-men-a-mathematical-modelling-study
#12
Luisa Salazar-Vizcaya, Roger D Kouyos, Jan Fehr, Dominique Braun, Janne Estill, Enos Bernasconi, Julie Delaloye, Marcel Stöckle, Patrick Schmid, Mathieu Rougemont, Gilles Wandeler, Huldrych F Günthard, Olivia Keiser, Andri Rauch
Increasing access to direct-acting antiviral (DAA)-treatment for hepatitis C virus (HCV) infection and decelerating the rise in high-risk behaviour over the next decade, could curb the HCV epidemic among HIV-positive men-who-have-sex-with-men (MSM). We investigated if similar outcomes would be achieved by short-term intensive interventions like the Swiss-HCVree-trial. We used a HCV-transmission model emulating two 12-months intensive-interventions combining risk-counselling with 1) universal DAA-treatment (pangenotypic intervention) and 2) DAA-treatment for HCV-genotypes 1 and 4 (replicating the Swiss-HCVree-trial)...
July 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28652072/evaluation-of-a-hepatitis-c-education-intervention-with-clients-enrolled-in-methadone-maintenance-and-needle-syringe-programs-in-malaysia
#13
Trena I Mukherjee, Veena Pillai, Siti Hafizah Ali, Frederick L Altice, Adeeba Kamarulzaman, Jeffrey A Wickersham
BACKGROUND: Approximately 40%-90% of people who inject drugs (PWID) in Malaysia have hepatitis C (HCV). PWID continue to be disproportionately affected by HCV due to their lack of knowledge, perceived risk and interest in HCV treatment. Education interventions may be an effective strategy for increasing HCV knowledge in PWID, and harm reduction services are uniquely positioned to implement and deploy such interventions. METHODS: We recruited 176 clients from methadone maintenance treatment (MMT: N=110) and needle/syringe programs (NSP: N=66) between November 2015 and August 2016...
June 23, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28648305/assessing-the-budget-impact-and-economic-outcomes-of-the-introduction-of-daclatasvir-asunaprevir-and-sofosbuvir-ledipasvir-for-the-treatment-of-chronic-hepatitis-c-virus-infection-in-japan
#14
Thomas Ward, Samantha Webster, Sari Mishina, Phil McEwan, Gail Wygant, Feng Wang
BACKGROUND: The advent of highly efficacious, well-tolerated, all-oral direct-acting antiviral regimens has revolutionized the standard of care for patients chronically infected with hepatitis C virus. As efficacy and safety rates converge, prescribers and payers need to consider value for money. OBJECTIVES: To evaluate the health economic value of daclatasvir + asunaprevir versus sofosbuvir/ledipasvir via a cost-effectiveness analysis, and determine the optimal treatment considering both costs and health outcomes in Japan...
May 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/28647541/response-tailored-protocol-versus-the-fixed-12weeks-course-of-dual-sofosbuvir-daclatasvir-treatment-in-egyptian-patients-with-chronic-hepatitis-c-genotype-4-infection-a-randomized-open-label-non-inferiority-trial
#15
Mostafa Yakoot, Alaa M Abdo, Siham Abdel-Rehim, Sherine Helmy
BACKGROUND: The most recent European Association for the Study of the Liver (EASL) 2016 Guidelines on treatment of hepatitis C (HCV), allowed for shortening the course of treatment for some subsets of patients with sofosbuvir/ledipasvir and with grazoprevir/elbasvir based on cutoff baseline HCV RNA values. We hypothesized that it would be prudent to also consider an objectively assuring very rapid, on-treatment, virologic response to therapy at week 2 (vRVR) before taking the decision of shortening the treatment duration...
May 17, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28645446/cost-effectiveness-analysis-of-two-treatment-strategies-for-chronic-hepatitis-c-before-and-after-access-to-direct-acting-antivirals-in-spain
#16
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado
OBJECTIVE: To evaluate the cost-effectiveness of a strategy based on direct-acting antivirals (DAAs) following the marketing of simeprevir and sofosbuvir (post-DAA) versus a pre-direct-acting antiviral strategy (pre-DAA) in patients with chronic hepatitis C, from the perspective of the Spanish National Health System. METHODS: A decision tree combined with a Markov model was used to estimate the direct health costs (€, 2016) and health outcomes (quality-adjusted life years, QALYs) throughout the patient's life, with an annual discount rate of 3%...
June 20, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28643186/current-progress-in-host-innate-and-adaptive-immunity-against-hepatitis-c-virus-infection
#17
REVIEW
Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang, Fu-Sheng Wang
Hepatitis C virus (HCV) infects more than 170 million people worldwide and is the main cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Although the newly developed direct-acting antivirals (DAAs) have transformed the treatment of HCV infection, controlling HCV infection on a global scale remains a challenge because of the high cost, low resistance barrier of DAAs and lack of HCV vaccine. The host immune responses associated with HCV infection, especially HCV-specific T cellular immunity, determine the outcome of HCV infection: either acute or chronic infection...
June 22, 2017: Hepatology International
https://www.readbyqxmd.com/read/28634131/cost-effectiveness-of-pre-versus-post-liver-transplant-hepatitis-c-treatment-with-direct-acting-antivirals
#18
Sumeyye Samur, Brian Kues, Turgay Ayer, Mark S Roberts, Fasiha Kanwal, Chin Hur, Drew Michael S Donnell, Raymond T Chung, Jagpreet Chhatwal
BACKGROUND & AIMS: Oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment offer new hope to both pre- and post-liver transplant (LT) patients. However, whether to treat HCV patients pre- versus post-LT is not clear, as treatment can improve liver function but could reduce the chance of receiving a LT while on the waiting list. Our objective was to evaluate the cost-effectiveness of pre-LT versus post-LT HCV treatment with oral DAAs in decompensated cirrhotic patients on the LT waiting list...
June 17, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28631044/-personalized-treatment-of-viral-hepatitis-of-the-present-and-the-future-hepatitis%C3%A2-b-c-delta-and-e
#19
REVIEW
R Bartenschlager, M Cornberg, T Pietschmann
Precision medicine is also possible for infectious diseases as shown for the treatment of chronic viral hepatitis, especially if different options are available. In hepatitis B virus (HBV) infection, treatment indication as well as the choice of treatment and the decisions to stop treatment are based on viral markers and alanine aminotransferase (ALT) level. Future therapies for HBV infection aiming for functional cure or even virus elimination may be even more personalized and have to take into account the immune status of a given patient...
June 19, 2017: Der Internist
https://www.readbyqxmd.com/read/28628931/-the-probabilistic-efficiency-frontier-a-value-assessment-of-treatment-options-in-hepatitis-c
#20
Axel C Mühlbacher, Andrew Sadler
Background The German Institute for Quality and Efficiency in Health Care (IQWiG) recommends the concept of the efficiency frontier to assess health care interventions. The efficiency frontier supports regulatory decisions on reimbursement prices for the appropriate allocation of health care resources. Until today this cost-benefit assessment framework has only been applied on the basis of individual patient-relevant endpoints. This contradicts the reality of a multi-dimensional patient benefit. Objective The objective of this study was to illustrate the operationalization of multi-dimensional benefit considering the uncertainty in clinical effects and preference data in order to calculate the efficiency of different treatment options for hepatitis C (HCV)...
June 19, 2017: Das Gesundheitswesen
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"